Trial Outcomes & Findings for Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes (NCT NCT00585325)

NCT ID: NCT00585325

Last Updated: 2018-03-07

Results Overview

A pain assessment tool performed immediately after the dressing change was used to rate pain experienced during the dressing change. For this tool, pain was rated on a scale from 0-10 (0=no pain and 10=worst possible pain)

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

15 participants

Primary outcome timeframe

During dressing change

Results posted on

2018-03-07

Participant Flow

A total of 15 patients were enrolled with 41 VAC dressing changes. Patients could be enrolled into more than one arm.

Unit of analysis: VAC dressing changes

Participant milestones

Participant milestones
Measure
Instilled 1% Lidocaine
5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
Instilled Placebo (0.9% Normal Saline)
receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
Overall Study
STARTED
10 20
13 21
Overall Study
COMPLETED
9 14
12 18
Overall Study
NOT COMPLETED
1 6
1 3

Reasons for withdrawal

Reasons for withdrawal
Measure
Instilled 1% Lidocaine
5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
Instilled Placebo (0.9% Normal Saline)
receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
Overall Study
Withdrawal by Subject
1
1

Baseline Characteristics

Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Instilled 1% Lidocaine
n=14 VAC dressing changes
5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
Instilled Placebo (0.9% Normal Saline)
n=18 VAC dressing changes
receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
Total
n=32 VAC dressing changes
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=99 Participants
10 Participants
n=107 Participants
18 Participants
n=206 Participants
Age, Categorical
>=65 years
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Sex: Female, Male
Female
7 Participants
n=99 Participants
6 Participants
n=107 Participants
13 Participants
n=206 Participants
Sex: Female, Male
Male
2 Participants
n=99 Participants
6 Participants
n=107 Participants
8 Participants
n=206 Participants
Region of Enrollment
United States
9 participants
n=99 Participants
12 participants
n=107 Participants
21 participants
n=206 Participants

PRIMARY outcome

Timeframe: During dressing change

A pain assessment tool performed immediately after the dressing change was used to rate pain experienced during the dressing change. For this tool, pain was rated on a scale from 0-10 (0=no pain and 10=worst possible pain)

Outcome measures

Outcome measures
Measure
Instilled 1% Lidocaine
n=14 VAC dressing changes
5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change Instilled 1% Lidocaine: 5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
Instilled Placebo (0.9% Normal Saline)
n=18 VAC dressing changes
receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change Placebo (0.9% Normal Saline): .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
Pain During Dressing Change
6.36 units on a scale
Standard Deviation 2.56
6.94 units on a scale
Standard Deviation 3.11

Adverse Events

Instilled 1% Lidocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Instilled Placebo (0.9% Normal Saline)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Cindy Schmitz, RN, MS, NP

University of Wisconsin-Madison

Phone: 608-262-2664

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place